Truist Securities Rates Progyny (PGNY) buy, $33 Price Target

Truist Securities maintains its Buy rating on PGNY, setting a target price of $33, a 26.53% upside from the current price.

By EarningsIQ Research Desk · Published Jun 22, 2026, 2:01 PM EDT · Updated Jun 22, 2026, 9:06 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Truist Securities rated Progyny, Inc. ($PGNY) "buy" with a $33 price target on June 22, 2026.

Since the rating, $PGNY is up 9.8% after 1 week, up 19.3% after 1 month and up 2.2% to date (from the $26.28 close on Jun 22, 2026).

PGNY Progyny, Inc.

$26.86 +4.35% year to date

Daily close · Oct 16, 2026

Key Points

Truist Securities reiterated its Buy rating on PGNY with a new price target of $33 on June 22, 2026.
Truist Securities's $33 price target implies 26.53% upside from Progyny, Inc.'s ($PGNY) current $26.08 share price.
PGNY shares traded at $26.08 on Monday, reflecting market confidence in the company's growth potential.
Recent insider transactions include planned sales by key executives, while institutional investors like BlackRock reduced their holdings.

Get $PGNY trade alerts by text

We text you when insiders, Congress or big funds trade $PGNY. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Progyny, Inc. alert may contain errors. Disclosures

On June 22, 2026, Truist Securities reiterated its Buy rating on PGNY, setting a target price of $33. This update comes as the company continues to attract attention from investors and analysts alike. PGNY shares traded at $26.08 on Monday, indicating a positive outlook from the market.

Analyst rating track record

Truist Securities vs. the S&P 500

YTD return -4.11% hypothetical

All-time return -0.51% S&P 500 +26.89%

vs. S&P 500 -27.40% behind the index

Hypothetical returns from Truist Securities's disclosed trades, not real profit or advice. How we model this.

Other Institutional Activity in PGNY

Several institutional investors have made notable changes to their PGNY holdings. BlackRock, Inc. reduced its position by 960,152 shares, leaving it with about 11.99 million shares valued at approximately $203.7 million, a 7.4% decrease. FMR LLC also trimmed its stake by 66,091 shares, ending with 6.5 million shares worth about $110.4 million, a 1.0% decrease. On the other hand, Vanguard Portfolio Management LLC and Vanguard Capital Management LLC both opened new positions in PGNY, acquiring 5,292,028 and 3,481,339 shares, respectively. State Street Corp increased its holdings by 127,107 shares to reach a total of 3,080,293 shares, a 4.3% rise, while Ameriprise Financial Inc boosted its stake by 547,282 shares to 2,825,331 shares, marking a 24.0% increase.

Progyny, Inc. Stock Down 3.9%

PGNY shares were trading near $26.08 on Monday. The stock has seen varied interest from institutional investors and analysts, reflecting its dynamic position in the market.

12-month forecast

$PGNY price target

Progyny, Inc. daily closes and this analyst's $33 target. Not advice.

Insider Buying and Selling at Progyny, Inc.

Recent insider activity at PGNY includes planned sales by key executives. On June 4, 2026, Mark Livingston, the Chief Financial Officer, sold 2,517 shares at an average price of $25.50 under a Rule 10b5-1 plan. Additionally, Allison Swartz, Executive Vice President and General Counsel, sold 599 shares at $25.08, also under a planned sale. There were additional unplanned sales by both Livingston and Swartz on the same date.

Analysts Set New Price Targets

On June 22, 2026, Truist Securities maintained its Buy rating on PGNY with a $33 price target. Earlier in the month, B of A Securities also maintained a Buy rating with a $31 target on June 2, 2026. Canaccord Genuity upgraded PGNY to a Buy with a $30 target on May 19, 2026. Barclays maintained its Buy rating with a $27 target on May 18, 2026, reflecting a consistent positive sentiment among analysts.

Bottom Line

Truist Securities' reiteration of its Buy rating and the new $33 price target for PGNY highlights ongoing confidence in the company's market potential. Institutional activity shows a mix of reductions and new entries, indicating diverse strategies among investors. Insider sales, particularly planned ones, are a regular part of executive financial management. As always, 13F filings and analyst ratings provide a backward-looking view and should be considered as part of a broader investment strategy.